Nom du produit:5,7-dichloro-3-isopropylpyrazolo[1,5-a]pyrimidine

IUPAC Name:5,7-dichloro-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidine

CAS:771510-32-8
Formule moléculaire:C9H9Cl2N3
Pureté:95%+
Numéro de catalogue:CM151764
Poids moléculaire:230.09

Unité d'emballage Stock disponible Prix($) Quantité
CM151764-100mg in stock ũƥ
CM151764-250mg in stock Ⱥȡ
CM151764-1g in stock ƛƥƛ
CM151764-5g in stock ȐũȺ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:771510-32-8
Formule moléculaire:C9H9Cl2N3
Point de fusion:-
Code SMILES:CC(C)C1=C2N=C(Cl)C=C(Cl)N2N=C1
Densité:
Numéro de catalogue:CM151764
Poids moléculaire:230.09
Point d'ébullition:
N° Mdl:MFCD12923044
Stockage:Store at 2-8°C.

Category Infos

Pyrazolopyrimidines
Pyrazolopyrimidine scaffolds are one of the most important heterocyclic compounds in drug discovery. This scaffold has various biological activities, among which anticancer is an important one.

Column Infos

Samuraciclib
Carrick Therapeutics’ Phase 2 Clinical Trial of Samuraciclib combined with Fulvestrant has dosed its first patient. The study targets patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer. Samuraciclib is a selective oral, first-in-class inhibitor of CDK7. It is involved in the regulation of cancer-causing genes, promotion of uncontrolled cell cycle progression, and increase in resistance to anti-hormone therapy. The comb previously receives the Fast Track Designation from the U.S. FDA.

Related Products